Merck Says FDA Approved Labeling Update For ISENTRESS - Quick Facts - RTT News

(RTTNews) - Merck (MRK: News ) said the FDA approved a labeling update for ISENTRESS (raltegravir) Film-coated Tablets to include 156-week data from the STARTMRK study with ISENTRESS in combination therapy compared to efavirenz in combination therapy in ...

Walt Disney and 2 Dow 30 Stocks Making Waves - Wall St. Cheat Sheet

Merck & Co. Inc. (NYSE:MRK) has been granted FDA approval for a labeling update for Isentress Film-coated Tablets, which include 156 weeks of data from the StartMRK evaluation with Isentress, in combination therapy compared to efavirenz in combination ...

FDA ADAC recommends approval of Quad for HIV-1 infection - News-Medical.Net

The Quad NDA is supported by the positive results from two pivotal Phase 3 studies in which Quad met its primary objective of non-inferiority as compared to Atripla ® (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg ...

UGANDA: Rising ARV resistance threatens HIV fight - IRIN

Most patients had resistance to a class of ARVs called non-nucleoside reverse transcriptase inhibitors (NNRTIs), which include commonly used medications such as nevirapine and efavirenz. The report revealed that poor treatment adherence to ARVs ...

FDA Review Positive on Quad Pill for HIV - MedPage Today

If eventually approved, the quad pill would be the third single-pill, once-daily complete regimen for HIV, along with Atripla (efavirenz, emtricitabine, and tenofovir) and Complera (rilpivirine, emtricitabine, and tenofovir). All four drugs in ...

Tanzania Pharmaceuticals and Healthcare Report Q3 2012 - new market research report - Transworld News

Key Trends And Developments • In positive news for the Tanzanian population, the commercial production of country's first locally manufactured ARV drugs, including a first-line ARV, efavirenz, are due to begin. The manufacturing plant, in the northern ...

HIV Treatment Study in Patients with Cryptococcal Meningitis Ends Enrollment Early - Healthcanal.com

Antiretroviral therapy included an efavirenz-based regimen in accordance with national treatment guidelines, The study was slated to end in June 2015. Participants are being notified of the study’s developments and will continue to be followed by study staff.

FDA Advisory Committee Supports Approval of Gilead’s Truvada® for Reducing the Risk of Acquiring HIV - Yahoo Finance

Common side effects reported during clinical studies with Truvada (in combination with efavirenz) include diarrhea, nausea, fatigue, headache, dizziness, depression, insomnia, abnormal dreams and rash. Caution should be exercised when co ...

FDA Advisory Committee Supports Approval of Gilead’s Once-Daily Quad Single Tablet Regimen for HIV - Yahoo Finance

The Quad NDA is supported by the positive results from two pivotal Phase 3 studies in which Quad met its primary objective of non-inferiority as compared to Atripla ® (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg ...